Evofem Biosciences Inc expected to post a loss of 21  cents a share - Earnings Preview

Evofem Biosciences

03/05/2022 03:11

* Evofem Biosciences Inc  EVFM.OQ   EVFM.O  is expected
to show a
rise in quarterly revenue when it reports  results on May 4. 
    * The San Diego California-based  company is expected to
report  a
276.0% increase in revenue to $4.155 million from $1.11 million
a year ago, according to the mean estimate from 2 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Evofem Biosciences
Inc is
for a loss of 21 cents per share. For the same quarter last
year, the company reported a loss of 56 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and 1 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Evofem
Biosciences Inc is $2​, above​ its last closing price of $0.16.
​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2021  -0.22       -0.23      -0.33     Missed  -45.1
 Sep. 30 2021  -0.30       -0.29      -0.48     Missed  -62.7
 Jun. 30 2021  -0.37       -0.37      -0.27     Beat    26.5​
 Mar. 31 2021  -0.49       -0.49      -0.56     Missed  -14.9
 ​​Dec.        -0.40       -0.36      -0.50     Missed  -37.9
 31 2020                                                
 Sep. 30 2020  -0.44       -0.44      -0.37     Beat    15.9​
 Jun. 30 2020  -0.37       -0.37      -0.91     Missed  -143.8
 Mar. 31 2020  -0.33       -0.32      -0.40     Missed  -25
 This summary was machine generated May 3 at 02:11 GMT.  All
figures in US dollars  unless otherwise stated